SCHEMBL21295539

SCHEMBL21295539

COCCOc1cc(N)ccc1Oc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.50
NTRK3 Q16288 4/20 0.50
NTRK2 Q16620 4/20 0.50
TTR P02766 3/20 0.43
MAOB P27338 1/20 0.42
MAOA P21397 1/20 0.42
BRD4 O60885 2/20 0.41
GAA P10253 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30744009 1.00 NTRK1 (0.50) NTRK1NTRK3NTRK2TTRMAOB
SCHEMBL4061067 0.84 ALDH1A1 (0.55) GAAKDM4EALDH1A1MAPTMEN1
SCHEMBL29736247 0.84 ALDH1A1 (0.55) GAAKDM4EALDH1A1MAPTMEN1
SCHEMBL5548836 0.83 MAPT (0.56) NTRK1NTRK3NTRK2TTRMAOB
SCHEMBL21340417 0.83 L3MBTL1 (0.48) NTRK1NTRK3NTRK2MAOBMAOA
SCHEMBL14937721 0.81 MAPT (0.50) GAAKDM4EALDH1A1MAPTMEN1
SCHEMBL15814937 0.81 CYP19A1 (0.50) MAOBMAOAGAAMAPTKMT2A
SCHEMBL3811355 0.80 TTR (0.58) NTRK1NTRK2TTRMAOBMAOA
SCHEMBL30222339 0.80 TTR (0.58) NTRK1NTRK2TTRMAOBMAOA
SCHEMBL5649965 0.80 KDM4E (0.56) GAAKDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 US disclosed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
EP-3759088-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2021-01-06 EP disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
CN-111819172-A Triazine derivatives for the treatment of neurotrophin-related disorders 阿泽克制药公司 2020-10-23 CN disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK3 5/4885NTRK2 1/4885
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK3 5/4885NTRK2 1/4885
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins NTRK2, BDNF, NGF NTRK1 13/4885NTRK3 6/4885NTRK2 1/4885
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 13/4885NTRK3 6/4885NTRK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.